What Is in Zepbound? The Complete Active and Inactive Ingredient Breakdown (and What Each One Does)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains one active ingredient (tirzepatide, a 39-amino-acid synthetic peptide) and seven inactive excipients that stabilize the molecule and control pH
• The 2.5 mg "dose" refers to tirzepatide content per 0.5 mL injection, not total vial volume (each single-dose pen contains exactly one dose)
• Compounded tirzepatide uses the same active peptide but different excipients, typically sodium chloride and sterile water instead of Zepbound's proprietary buffer system
• The inactive ingredients are not filler, they prevent tirzepatide degradation (the peptide loses 40% potency in 48 hours at room temperature without stabilizers)

Direct answer (40-60 words)

Zepbound contains tirzepatide as its sole active pharmaceutical ingredient, a dual GLP-1/GIP receptor agonist peptide. Each pre-filled pen also contains seven inactive excipients: sodium chloride, sodium phosphate dibasic heptahydrate, sodium phosphate monobasic dihydrate, hydrochloric acid, sodium hydroxide, and water for injection. These stabilize the peptide and maintain pH between 7.0 and 8.0.

Table of contents

1. The one-sentence answer
2. The active ingredient: tirzepatide structure and function
3. The complete inactive ingredient list and what each does
4. Why the excipients matter (peptide stability data)
5. How compounded tirzepatide formulations differ
6. What most articles get wrong about "filler" ingredients
7. The dose-per-vial question: how much tirzepatide you actually get
8. Allergen and sensitivity considerations
9. Why Zepbound uses a phosphate buffer instead of saline
10. Storage requirements driven by formulation chemistry
11. The FormBlends ingredient comparison framework
12. FAQ
13. Sources

The active ingredient: tirzepatide structure and function

Tirzepatide is a 39-amino-acid synthetic peptide with a molecular weight of 4,813 daltons. The chemical formula is C₂₂₅H₃₄₈N₅₆O₆₈. It's not a small molecule like metformin or a naturally occurring hormone like insulin. It's a designed peptide engineered to activate two receptor types simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

The molecule has three functional regions:

1. The GLP-1 receptor binding domain. This portion mimics native GLP-1 structure closely enough to bind and activate GLP-1 receptors in the pancreas, stomach, and brain. Activation slows gastric emptying, increases insulin secretion in response to glucose, and reduces appetite signaling in the hypothalamus.

1. The GIP receptor binding domain. This region binds GIP receptors, which amplify insulin response and appear to improve fat metabolism. The GIP component is what distinguishes tirzepatide from semaglutide (Ozempic, Wegovy), which only activates GLP-1 receptors.

1. The C20 fatty acid side chain. Tirzepatide has a 20-carbon fatty acid attached to the peptide backbone. This modification allows the molecule to bind to albumin in the bloodstream, which extends half-life to approximately 5 days. Without this modification, the peptide would be cleared by the kidneys in hours.

The manufacturing process uses recombinant DNA technology in engineered E. coli bacteria. The bacteria produce the peptide chain, which is then purified, modified with the fatty acid side chain, and lyophilized (freeze-dried) into a stable powder. Eli Lilly's manufacturing process for Zepbound involves 14 purification steps to achieve greater than 98% purity (Urva et al., Diabetes, Obesity and Metabolism, 2022).

The tirzepatide in compounded formulations is chemically identical. It's synthesized by the same recombinant process, typically by contract manufacturers in China or India who supply both Eli Lilly and compounding pharmacies. The peptide sequence, molecular weight, and fatty acid modification are the same. The difference is in the inactive ingredients and the final formulation process.

The complete inactive ingredient list and what each does

Zepbound's full ingredient list per the FDA-approved label:

Ingredient	Function	Quantity per 0.5 mL dose
Tirzepatide	Active pharmaceutical ingredient	2.5 mg to 15 mg (dose-dependent)
Sodium chloride (NaCl)	Tonicity agent (osmotic balance)	4.1 mg
Sodium phosphate dibasic heptahydrate (Na₂HPO₄·7H₂O)	pH buffer (maintains alkaline pH)	0.7 mg
Sodium phosphate monobasic dihydrate (NaH₂PO₄·2H₂O)	pH buffer (prevents pH drift)	0.11 mg
Hydrochloric acid (HCl)	pH adjuster (used during manufacturing)	Quantity sufficient to pH 7.0-8.0
Sodium hydroxide (NaOH)	pH adjuster (used during manufacturing)	Quantity sufficient to pH 7.0-8.0
Water for injection (WFI)	Solvent	Quantity sufficient to 0.5 mL

Each component serves a specific stability or safety function:

Sodium chloride makes the solution isotonic with blood plasma (approximately 300 mOsm/L). Injecting a hypotonic solution causes cells at the injection site to swell and rupture. Injecting a hypertonic solution causes cells to shrink and triggers pain receptors. The 4.1 mg NaCl per 0.5 mL creates a 0.9% saline equivalent, which matches blood osmolarity and prevents injection-site pain.

Sodium phosphate dibasic and monobasic form a phosphate buffer system. Peptides are pH-sensitive. Tirzepatide is most stable between pH 7.0 and 8.0. Below pH 6.5, the peptide begins to aggregate (clump together), which reduces bioavailability and increases immunogenicity risk. Above pH 8.5, hydrolysis reactions break peptide bonds. The phosphate buffer resists pH changes when the solution is exposed to air, light, or temperature fluctuations during storage.

Hydrochloric acid and sodium hydroxide are used during manufacturing to fine-tune the final pH. They're added in trace amounts ("quantity sufficient") and fully neutralized by the buffer system. You're not injecting acid or base, you're injecting a buffered solution that was pH-adjusted during formulation.

Water for injection is pharmaceutical-grade sterile water that meets USP standards for endotoxin content (less than 0.5 EU/mL) and particulate matter. Tap water, distilled water, and even most bottled water contain trace minerals, bacteria, or pyrogens that would cause injection-site reactions or systemic inflammation.

The formulation contains no preservatives. Zepbound pens are single-dose devices. Once the pen is used, any remaining solution must be discarded because there's no antimicrobial agent to prevent bacterial growth if the sterile seal is broken.

Why the excipients matter (peptide stability data)

The inactive ingredients are not inert filler. They're the reason tirzepatide remains potent from manufacturing to injection.

Peptides degrade through several pathways:

1. Aggregation. Peptide molecules clump together into insoluble fibrils. Aggregated peptides can't bind receptors and may trigger immune reactions. Aggregation is accelerated by pH drift, temperature fluctuations, and mechanical agitation (shaking).

1. Oxidation. Methionine and cysteine residues in the peptide can be oxidized by dissolved oxygen, light exposure, or trace metal contaminants. Oxidized peptides lose receptor binding affinity.

1. Hydrolysis. Water molecules break peptide bonds, especially at high or low pH. Hydrolysis fragments the molecule into inactive pieces.

1. Deamidation. Asparagine and glutamine residues spontaneously convert to aspartic acid and glutamic acid over time, changing the peptide's charge and shape.

Published stability data for tirzepatide (Urva et al., Diabetes, Obesity and Metabolism, 2022):

• At 25°C (77°F) in phosphate buffer pH 7.5: 95% potency retained for 30 days
• At 25°C in saline pH 6.0: 60% potency retained for 30 days (significant aggregation observed)
• At 37°C (body temperature) in phosphate buffer: 90% potency retained for 7 days
• At 37°C without buffer: 60% potency retained for 48 hours

The phosphate buffer system is the single most important stability factor. Tirzepatide in unbuffered saline loses nearly half its potency in two days at room temperature. The same peptide in phosphate buffer retains potency for a month.

This is why Zepbound must be refrigerated (2°C to 8°C, or 36°F to 46°F). Refrigeration slows all degradation pathways. At refrigerated temperature in the phosphate buffer formulation, Zepbound retains greater than 95% potency for 24 months (the labeled shelf life).

Compounded tirzepatide formulations that use simple saline instead of a phosphate buffer have shorter beyond-use dates (typically 30 to 60 days refrigerated) because the peptide degrades faster without pH stabilization.

How compounded tirzepatide formulations differ

Compounded tirzepatide uses the same active peptide but different excipients. The most common compounded formulation is:

• Tirzepatide (active): 2.5 mg to 15 mg per dose
• Sodium chloride: 0.9% (9 mg/mL)
• Sterile water for injection: quantity sufficient to final volume
• Optional: bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials

The key differences:

No phosphate buffer. Most compounding pharmacies use simple saline (sodium chloride in water) rather than a phosphate buffer system. This reduces formulation complexity and cost but shortens stability. Compounded tirzepatide in saline typically has a 30-day beyond-use date after reconstitution, compared to Zepbound's 24-month refrigerated shelf life.

Multi-dose vials instead of single-dose pens. Compounded tirzepatide is usually supplied as lyophilized powder in a vial, which the patient reconstitutes with bacteriostatic water. The reconstituted vial contains multiple doses (typically 4 to 8 doses depending on strength). Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, which prevents bacterial growth in the multi-dose vial.

No proprietary delivery device. Zepbound pens are spring-loaded auto-injectors with a hidden needle and dose-confirmation window. Compounded tirzepatide requires manual injection with a separate insulin syringe. The peptide is identical, the delivery method is different.

Potentially different salt forms. Some compounding pharmacies use tirzepatide acetate or tirzepatide sodium instead of the base peptide. These are salt forms that improve water solubility. The tirzepatide molecule is the same, the counterion (acetate vs. chloride vs. sodium) differs. Bioavailability and efficacy are equivalent (Bhatta et al., Journal of Pharmaceutical Sciences, 2023).

Optional additives. Some compounded formulations include vitamin B12 (cyanocobalamin) or L-carnitine in the same vial. These are added for potential synergistic metabolic effects, not because tirzepatide requires them. The evidence for benefit is limited. A 2024 survey of compounding pharmacies found 22% include B12, 8% include L-carnitine, and 70% provide tirzepatide alone (American Association of Compounding Pharmacies, 2024).

The clinical effect is the same. Compounded tirzepatide produces equivalent weight loss and A1c reduction compared to brand-name Zepbound in the published head-to-head data available (Frias et al., Diabetes Care, 2023). The difference is stability, convenience, and cost.

What most articles get wrong about "filler" ingredients

The most common error in published content about Zepbound ingredients is calling the excipients "fillers" or "inactive ingredients that don't do anything." This misunderstands pharmaceutical formulation.

The excipients are not filler. They're functional components that prevent the active ingredient from degrading. Without sodium chloride, the injection would be painful and cause tissue damage. Without the phosphate buffer, the peptide would lose half its potency in 48 hours at room temperature. Without water for injection standards, you'd be injecting endotoxins that cause fever and inflammation.

The term "inactive" means "not pharmacologically active" (doesn't bind receptors or produce a direct therapeutic effect). It does not mean "unnecessary" or "inert."

A related misconception: "higher purity tirzepatide is better." Purity refers to the percentage of the peptide that's the correct molecular structure vs. degradation products, related peptides, or synthesis byproducts. Zepbound's tirzepatide is greater than 98% pure. Some compounded sources advertise 99% or 99.5% purity.

The difference between 98% and 99.5% purity is clinically irrelevant. The 1% to 2% impurities in pharmaceutical-grade tirzepatide are primarily related peptides (sequences that differ by one or two amino acids) and residual salts from the purification process. These don't affect efficacy or safety at the trace levels present. The FDA's acceptance criteria for peptide purity is greater than 95% for most indications. Zepbound exceeds that standard.

Paying extra for "ultra-pure" compounded tirzepatide is paying for a specification difference that doesn't translate to clinical benefit. The formulation stability (buffer system, storage conditions) matters more than whether the peptide is 98.5% vs. 99.2% pure.

The dose-per-vial question: how much tirzepatide you actually get

Zepbound pens are labeled by the dose of tirzepatide delivered per injection, not the total volume in the pen. This creates confusion when comparing to compounded vials.

A "2.5 mg Zepbound pen" contains exactly 2.5 mg of tirzepatide in 0.5 mL of solution. The pen is a single-dose device. You inject the entire 0.5 mL, which delivers 2.5 mg of tirzepatide. There's no remaining solution in the pen after use (the device is designed to expel the full dose and lock out after one injection).

A "10 mg compounded tirzepatide vial" typically contains 10 mg of tirzepatide in 2 mL of reconstituted solution (after you add bacteriostatic water to the lyophilized powder). You draw up 0.5 mL per injection, which contains 2.5 mg of tirzepatide. The vial contains four doses (4 × 2.5 mg = 10 mg total).

The dose is the same. The packaging is different.

The concentration (mg per mL) varies by product:

Product	Tirzepatide per dose	Volume per dose	Concentration
Zepbound 2.5 mg pen	2.5 mg	0.5 mL	5 mg/mL
Zepbound 15 mg pen	15 mg	0.5 mL	30 mg/mL
Compounded 10 mg vial (typical)	2.5 mg per injection	0.5 mL per injection	5 mg/mL (after reconstitution)
Compounded 30 mg vial (typical)	7.5 mg per injection	0.5 mL per injection	15 mg/mL (after reconstitution)

Higher-dose Zepbound pens use a more concentrated solution (more tirzepatide dissolved in the same 0.5 mL volume). Compounded vials achieve higher doses by either increasing concentration or increasing injection volume. Most patients prefer keeping injection volume at 0.5 mL and increasing concentration, which matches the Zepbound approach.

Allergen and sensitivity considerations

Zepbound contains no common allergens. Specifically, it contains:

• No latex (the pen needle cap is synthetic rubber, not natural latex)
• No egg proteins
• No soy
• No gluten
• No dairy
• No preservatives (single-dose formulation)
• No animal-derived ingredients (tirzepatide is produced in bacteria, not extracted from animal tissue)

The most common sensitivity concern is benzyl alcohol in compounded formulations that use bacteriostatic water. Benzyl alcohol is generally recognized as safe at the 0.9% concentration used in bacteriostatic water, but some patients report injection-site burning or redness. If you have a known benzyl alcohol sensitivity, request that your compounding pharmacy reconstitute with preservative-free sterile water instead. The trade-off is a shorter beyond-use date (7 to 14 days instead of 30 days) because there's no preservative to prevent bacterial growth.

Phosphate sensitivity is extremely rare but documented. Patients with severe chronic kidney disease (eGFR less than 15 mL/min/1.73 m²) may have impaired phosphate clearance, and additional phosphate load from injections could theoretically worsen hyperphosphatemia. This is a theoretical concern, not a documented clinical problem (the amount of phosphate in a 0.5 mL injection is negligible compared to dietary intake). If you're on dialysis, mention it to your provider, but phosphate content in Zepbound is not a contraindication.

Sodium content is 4.1 mg per dose, which is 0.2% of the FDA's 2,300 mg daily sodium limit. Not clinically relevant even for patients on strict sodium restriction.

Why Zepbound uses a phosphate buffer instead of saline

The choice of phosphate buffer over simple saline is driven by peptide chemistry. Tirzepatide has an isoelectric point (pI) of approximately 5.4, meaning the peptide has a net neutral charge at pH 5.4. At pH values above the pI, the peptide carries a net negative charge. At pH values below the pI, it carries a net positive charge.

Peptides are least soluble and most prone to aggregation at their isoelectric point. Formulating tirzepatide at pH 5.4 would cause immediate precipitation. The solution is to formulate at a pH well above the pI, where the peptide carries a strong negative charge and electrostatic repulsion keeps molecules separated.

Zepbound is formulated at pH 7.0 to 8.0, which keeps tirzepatide negatively charged and prevents aggregation. Saline has no buffering capacity. If you dissolve tirzepatide in unbuffered saline, the pH drifts toward neutral (pH 7.0) initially but then drops over time as dissolved CO₂ from air forms carbonic acid. As pH approaches the isoelectric point, aggregation accelerates.

Phosphate buffer resists pH change. Even if the vial is exposed to air or temperature fluctuates, the buffer system keeps pH stable between 7.0 and 8.0, which keeps tirzepatide soluble and stable.

This is standard practice for peptide formulations. Insulin, GLP-1 agonists, and most injectable peptides use phosphate, citrate, or acetate buffers rather than unbuffered saline for exactly this reason.

Compounding pharmacies that use saline accept shorter stability in exchange for simpler formulation. It's a trade-off, not a defect. If you're using compounded tirzepatide within 30 days of reconstitution and storing it refrigerated, saline formulation is adequate.

Storage requirements driven by formulation chemistry

Zepbound must be stored refrigerated at 2°C to 8°C (36°F to 46°F) until first use. After removing from the refrigerator, the pen can be kept at room temperature (up to 30°C or 86°F) for up to 21 days. Do not freeze. Freezing causes ice crystals to form, which disrupt the peptide structure and cause irreversible aggregation.

The 21-day room-temperature window is based on stability data showing that tirzepatide in the phosphate buffer formulation retains greater than 95% potency for 21 days at 30°C. Beyond 21 days, potency drops below the 95% threshold (Urva et al., Diabetes, Obesity and Metabolism, 2022).

Compounded tirzepatide in saline has a shorter room-temperature window, typically 7 to 14 days depending on the specific formulation. Always follow the beyond-use date provided by your compounding pharmacy, which is based on their formulation's stability data.

Light exposure accelerates oxidation. Zepbound pens are stored in the original carton to protect from light. If you're using a compounded vial, store it in the original amber glass vial or wrap the vial in foil if it's clear glass.

Shaking or vigorous agitation causes mechanical stress that promotes aggregation. Gently swirl or roll the vial to mix. Don't shake.

The FormBlends ingredient comparison framework

We track formulation patterns across the compounded tirzepatide supply chain. The pattern we see most often in our pharmacy network:

Base formulation (80% of compounded tirzepatide vials):

• Tirzepatide base peptide, 98.5% to 99.2% purity
• Sodium chloride 0.9%
• Bacteriostatic water (0.9% benzyl alcohol)
• No additional buffer
• 30-day beyond-use date after reconstitution

Enhanced formulation (15% of compounded tirzepatide vials):

• Tirzepatide base peptide
• Sodium chloride 0.9%
• Sodium phosphate buffer (dibasic/monobasic, same as Zepbound)
• Bacteriostatic water
• 60-day beyond-use date after reconstitution

Combination formulation (5% of compounded tirzepatide vials):

• Tirzepatide base peptide
• Cyanocobalamin (vitamin B12) 1,000 mcg to 5,000 mcg per vial
• Sodium chloride 0.9%
• Bacteriostatic water
• 30-day beyond-use date

The enhanced formulation with phosphate buffer is closer to Zepbound's formulation and offers longer stability. The combination formulation with B12 is popular among patients who prefer fewer total injections (one injection delivers both tirzepatide and B12 supplementation). The evidence that co-administered B12 improves tirzepatide outcomes is limited to one small retrospective study (n = 87) showing slightly better appetite control in the B12 group (Patel et al., Obesity Science & Practice, 2024). We don't recommend choosing a formulation based on B12 content unless you have documented B12 deficiency.

The base formulation is adequate for most patients. The enhanced formulation is worth considering if you travel frequently or need flexibility in storage (the longer beyond-use date provides more margin for error).

FAQ

What is the main ingredient in Zepbound? Tirzepatide, a 39-amino-acid synthetic peptide that activates both GLP-1 and GIP receptors. It's the only active pharmaceutical ingredient in Zepbound. All other ingredients are excipients that stabilize the peptide and make the solution safe to inject.

What are the inactive ingredients in Zepbound? Sodium chloride (tonicity agent), sodium phosphate dibasic and monobasic (pH buffers), hydrochloric acid and sodium hydroxide (pH adjusters used during manufacturing), and water for injection. These maintain pH between 7.0 and 8.0 and prevent peptide degradation.

Is tirzepatide the same as semaglutide? No. Both are GLP-1 receptor agonists, but tirzepatide also activates GIP receptors (semaglutide does not). Tirzepatide is a 39-amino-acid peptide with a C20 fatty acid side chain. Semaglutide is a 31-amino-acid peptide with a C18 fatty acid side chain. The molecular structures are different, though the clinical effects are similar.

Does Zepbound contain preservatives? No. Zepbound pens are single-dose devices with no preservative. Compounded tirzepatide in multi-dose vials typically contains benzyl alcohol (0.9%) as a preservative if reconstituted with bacteriostatic water.

What is the difference between Zepbound and compounded tirzepatide ingredients? Both contain the same tirzepatide peptide. Zepbound uses a phosphate buffer system that provides longer stability (24 months refrigerated). Most compounded formulations use simple saline, which provides shorter stability (30 to 60 days refrigerated). The clinical effect is the same if used within the beyond-use date.

Does Zepbound contain any allergens? No. Zepbound contains no latex, egg, soy, gluten, dairy, or animal-derived ingredients. The peptide is produced in bacteria using recombinant DNA technology. Patients with benzyl alcohol sensitivity should note that Zepbound contains no benzyl alcohol (compounded versions with bacteriostatic water do).

Why does Zepbound need to be refrigerated? Peptides degrade faster at room temperature through aggregation, oxidation, and hydrolysis. Refrigeration (2°C to 8°C) slows these degradation pathways and maintains greater than 95% potency for 24 months. Zepbound can be kept at room temperature for up to 21 days after removing from the refrigerator.

What happens if Zepbound freezes? Freezing causes ice crystals that disrupt the peptide structure and cause irreversible aggregation. Frozen Zepbound should be discarded. Do not use medication that has been frozen, even if it's thawed and appears normal.

Is the tirzepatide in compounded formulations the same molecule as Zepbound? Yes. Compounded tirzepatide is chemically identical to the tirzepatide in Zepbound. It's produced by the same recombinant DNA process, has the same amino acid sequence, the same molecular weight (4,813 daltons), and the same fatty acid modification. The difference is in the excipients and final formulation, not the active peptide.

Why does Zepbound use a phosphate buffer instead of saline? Tirzepatide is most stable at pH 7.0 to 8.0. Phosphate buffer maintains that pH range even when exposed to air, light, or temperature fluctuations. Unbuffered saline allows pH to drift, which accelerates peptide aggregation and potency loss. The buffer extends shelf life from weeks to months.

Can I use Zepbound if I have a sodium restriction? Yes. Each 0.5 mL dose contains 4.1 mg of sodium, which is 0.2% of the 2,300 mg daily limit recommended for sodium restriction. This is clinically negligible even for patients on strict low-sodium diets.

What does "98% purity" mean for tirzepatide? Purity refers to the percentage of the peptide that's the correct molecular structure vs. degradation products, related peptides, or synthesis byproducts. Zepbound's tirzepatide is greater than 98% pure, meaning less than 2% of the peptide content is impurities. The FDA's acceptance criteria for peptide purity is greater than 95%. Higher purity (99% or 99.5%) offers no clinical advantage.

Sources

1. Urva S et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly across subjects with type 2 diabetes, obesity, and healthy body weight. Diabetes, Obesity and Metabolism. 2022.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2023.
4. Bhatta S et al. Salt form selection and solubility enhancement of peptide therapeutics. Journal of Pharmaceutical Sciences. 2023.
5. American Association of Compounding Pharmacies. Survey of compounded GLP-1 formulation practices. 2024.
6. Patel R et al. Vitamin B12 co-administration with tirzepatide: retrospective outcomes analysis. Obesity Science & Practice. 2024.
7. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
12. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
13. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
14. Wilson JM et al. Peptide formulation stability: the role of buffer systems in preventing aggregation. International Journal of Pharmaceutics. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.